13,13-dimethyl-tetradecanoic acid methyl ester | 93815-58-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 13,13-dimethyl-tetradecanoic acid methyl ester
• 英文别名: 13,13-Dimethyl-tetradecansaeure-methylester；methyl 13,13-dimethyl tetradecanoate；Tetradecanoic acid, 13,13-dimethyl-, methyl ester；methyl 13,13-dimethyltetradecanoate
• CAS: 93815-58-8
• 化学式: C₁₇H₃₄O₂
• 分子量: 270.456
• InChiKey: HMVURCFETBBBBW-UHFFFAOYSA-N

物化性质

• 沸点：
  144 °C(Press: 1.6 Torr)
• 密度：
  0.864±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  19
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  13,13-dimethyl-tetradecanoic acid methyl ester 在 氢氧化钾 作用下， 生成 13,13-dimethyl-tetradecanoic acid
  参考文献：
  名称：

  Neo-fatty Acids¹

  摘要：

  DOI：

  10.1021/ja01167a092
• 作为产物：
  描述：

  (4,4-dimethyl-pentyl)-magnesium bromide 在 sodium 作用下， 以 乙醚 为溶剂， 生成 13,13-dimethyl-tetradecanoic acid methyl ester
  参考文献：
  名称：

  Streibl,M. et al., Collection of Czechoslovak Chemical Communications, 1964, vol. 29, p. 2522 - 2527

  摘要：

  DOI：

文献信息

• Palladium-Catalyzed Alkyl-Alkyl Cross-Coupling Reaction of 9-Alkyl-9-BBN Derivatives with Iodoalkanes Possessing β-Hydrogens
  作者：Tatsuo Ishiyama、Shigeru Abe、Norio Miyaura、Akira Suzuki

  DOI：10.1246/cl.1992.691

  日期：1992.4

  9-Alkyl-9-BBN derivatives undergo the cross-coupling reaction with primary iodoalkanes to give the coupling products in fairly good yields in the presence of a catalytic amount of Pd(PPh3)4 and K3PO4.

  9-烷基-9-BBN衍生物与初级碘代烷发生交叉偶联反应，在催化量的Pd(PPh3)4和K3PO4存在下，可得到产率相当高的偶联产物。
• 3-Substituted pentanedioic acids and derivatives thereof
  申请人：G. D. Searle & Co.

  公开号：US04554359A1

  公开（公告）日：1985-11-19

  This invention relates to methods of preventing or reducing the degradation of elastin and other proteins and thereby preventing or retarding the disease states caused by said degradation by administering compounds of the formula: ##STR1## or their pharmacologically acceptable salts.

  本发明涉及通过给予化合物的方法来预防或减少弹性蛋白和其他蛋白质的降解，从而预防或减缓由此降解引起的疾病状态，所述化合物的公式为：##STR1##或其药学上可接受的盐。
• 2' ,5' -Oligoadenylate analogs
  申请人：Koizumi Makoto

  公开号：US20050261235A1

  公开（公告）日：2005-11-24

  A 2-5A analog represented by the formula (1): wherein m is 0 or 1; n is 0 to 2; R 1 represents an alkoxy group having from 1 to 6 carbon atoms which may be substituted, an unprotected mercapto group, a mercapto group protected by a nucleic acid synthesis protecting group, or an alkylthio group having from 1 to 4 carbon atoms which may be substituted; R 2 , R 3 , R 4 , R 5 and R 6 represent an unprotected hydroxyl group, a hydroxyl group protected by a nucleic acid synthesis protecting group, an alkoxy group having from 1 to 6 carbon atoms which may be substituted, an unprotected mercapto group, a mercapto group protected by a nucleic acid synthesis protecting group, or an alkylthio group having from 1 to 4 carbon atoms which may be substituted; R 7 represents an oxygen atom, or a —O(CH 2 CH 2 O)q-group, wherein q is 2 to 6; R 8 represents a hydrogen atom, an alkyl group having from 1 to 6 carbon atoms which may be substituted, or a 5′-phosphorylated oligonucleotide analog which has one hydroxyl group removed from the 5′-phosphoric acid group; E 1 , E 2 , E 3 and E 4 represent a naturally occurring or modified nucleic acid unit, or a pharmacologically acceptable salt thereof.

  一种由公式（1）表示的2-5A模拟物，其中m为0或1；n为0至2；R1表示具有1至6个碳原子的烷氧基，可以被取代，未保护的巯基，通过核酸合成保护基保护的巯基，或者具有1至4个碳原子的烷硫基，可以被取代；R2、R3、R4、R5和R6表示未保护的羟基，通过核酸合成保护基保护的羟基，具有1至6个碳原子的烷氧基，可以被取代，未保护的巯基，通过核酸合成保护基保护的巯基，或者具有1至4个碳原子的烷硫基，可以被取代；R7表示氧原子，或者-O(CH2CH2O)q-基团，其中q为2至6；R8表示氢原子，具有1至6个碳原子的烷基，可以被取代，或者从5'-磷酸基团中去除一个羟基的5'-磷酸寡核苷酸类似物；E1、E2、E3和E4表示天然或修饰的核酸单元，或其药理学上可接受的盐。
• Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog
  申请人：Koizumi Makoto

  公开号：US20100035976A1

  公开（公告）日：2010-02-11

  A method of treating a tumor or a viral disease by administering to a human the following 2′,5′-oligoadenylate analog: Wherein m is 0; n is 0 or 1; R 1 is alkoxy substituted by hydroxyl, mercapto, alkylthio substituted by hydroxyl or X 1 —X 2 —X 3 —S—; R 2 , R 3 , R 4 , R 5 and R 6 are hydroxyl, mercapto, alkylthio substituted by hydroxyl or X 1 —X 2 —X 3 —S—; R 7 is oxygen, sulfur, —NH—, or —O(CH 2 CH 2 O)q-, wherein q is 2 to 6, or oxyalkyleneoxy; R 8 is hydrogen or a 5′-phosphorylated oligonucleotide which has one hydroxyl removed from the 5′-phosphoric acid; E 1 is K 2 ; E 2 is K 1 ; E 3 is K 2 or K 3 and E 4 is K 1 , K 2 or K 3 ; K 1 is K 2 is K 3 is B is adeninyl; A is alkylene; D is alkyl or alkenyl; X 1 is alkyl or phenyl; X 2 is —C(═O)O—, —OC(═O)— or —C(═O)S—; and X 3 is alkylene.

  一种通过向人体内注射以下2′，5′-寡腺苷酸类似物来治疗肿瘤或病毒性疾病的方法：其中m为0；n为0或1；R1为烷氧基，被羟基，巯基，被羟基的烷基硫代基或X1—X2—X3—S—取代的烷氧基；R2，R3，R4，R5和R6为羟基，巯基，被羟基的烷基硫代基或X1—X2—X3—S—；R7为氧，硫，—NH—，或—O(CH2CH2O)q-，其中q为2至6，或氧烷氧基；R8为氢或一个5′-磷酸寡核苷酸，其5′-磷酸上有一个羟基被去除；E1为K2；E2为K1；E3为K2或K3，E4为K1，K2或K3；K1，K2和K3为B为腺苷基；A为烷基；D为烷基或烯基；X1为烷基或苯基；X2为—C(═O)O—，—OC(═O)—或—C(═O)S—；X3为烷基。
• 3-Substituted hydroxypentanedioic acids, -hemiesters or -anhydrides
  申请人：G.D. Searle & Co.

  公开号：EP0156100A2

  公开（公告）日：1985-10-02

  This invention relates to compounds useful for preventing or reducing the degradation of elastin and other proteins and thereby preventing or retarding the disease states caused by said degradation having the formula: or their pharmacologically acceptable salts.

  本发明涉及可用于预防或减少弹性蛋白和其他蛋白质降解，从而预防或延缓由上述降解引起的疾病状态的化合物，这些化合物具有以下式子： 或其药理学上可接受的盐类。